GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, firstname.lastname@example.org
#CKH176 Human MMP9 ELISA Kit
Product name : Human MMP9 ELISA Kit
Catalog number : CKH176
Quantity: 1 x 96 tests
Supplier name : Cell Sciences
Data sheet: Ask more or other datasheet now !
About this Product :Human MMP9 ELISA Kit
## PRODUCT_NAME ## Warunki przechowywania: Zalecamy aby przechowywyanie odbywało się w temperaturze od 2 do 8 stopni Celsjusza. Zdecydowanie należy unikać zamrażania i rozmrażania produktu aby kit zachował swoją czułośc detekcji.
More Details about
Human Matrix Metallopeptidase 9 ELISA Kit
Catalog No: CKH176 Size: 1 x 96 wells
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that degrade extracellular matrix proteins. MMPs have been linked with a wide array of biological activities and play important roles during organ development and pathological processes. Collectively MMPs are key enzymes for the metabolism of extracellular matrix proteins, including fibrillar and non-fibrillar collagens, fibronectin, laminin and basement membrane or interstitial stroma glycoproteins. Under physiological conditions MMPs are involved in extracellular degradation and breakdown of matrix proteins during normal tissue remodelling processes such as wound healing, pregnancy, and angiogenesis. Human MMP9 is a 92 kDa glycoprotein that plays a significant role in matrix remodeling, enzyme modulation, and cytokine/growth factor activation. MMP9 is also known as gelatinase B based on its ability to degrade gelatin.
The Cell Sciences Human MMP9 ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human MMP9 pro and active forms in serum, plasma (Collect plasma using heparin as an anticoagulant. EDTA and Citrate are not recommended), cell culture supernatants and urine. This assay employs an antibody specific for human MMP9 coated on a 96-well plate. Standards and samples are pipetted into the wells and MMP9 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human MMP9 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of MMP9 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Reagents and materials supplied with the kit:
Storage of Kit Reagents
Stable for up to 6 months from date of shipment at 2-4oC. Store reconstituted standard (recombinant protein) at -80oC. Opened Microplate Wells and reagents are stable for 1 month at 2-4oC. Return unused wells to the pouch containing desiccant pack and reseal along the entire edge. Kit is stable for one year if entire kit stored at -20oC.
Materials/reagents required but not provided:
• Microplate reader capable of measuring absorbance at 450 nm
• Precision pipettes to deliver 2 μl to 1 ml volumes
• Adjustable 1-25 ml pipettes for reagent preparation
• 100 ml and 1 liter graduated cylinders
• Absorbent paper
• Distilled or deionized water
• Log-log graph paper or computer and software for ELISA data analysis
• Tubes to prepare standard or sample dilutions
Preparation of Kit Reagents
1. Bring all reagents and samples to room temperature (18 - 25°C) before use.
2. Sample dilution: If your samples need to be diluted, Assay Diluent (Item E) is used for dilution of serum/plasma/culture supernatants/urine.
3. Assay Diluent (Item E) should be diluted 5-fold with deionized or distilled water before use.
4. Preparation of standard: Briefly spin the vial of Item C. Add 400 μl 1x Assay Diluent (Item E) into Item C vial to prepare a 50 ng/ml standard. Dissolve the powder thoroughly by a gentle mix. Add 80 μl MMP-9 standard from the vial of tem C, into a tube with 586.7 μl 1x Assay Diluent Buffer to prepare a 6000 pg/ml stock standard solution. Pipette 400μl 1x Assay Diluent into each tube. Use the stock standard solution to produce a Dilution series (shown below). Mix each tube thoroughly before the next transfer. Gently vortex to mix. 1x Assay Diluent serves as the zero standard (0 pg/ml).
5. If the Wash Concentrate (20x) (Item B) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 20 ml of Wash Buffer Concentrate into deionized or distilled water to yield 400 ml of 1x Wash Buffer.
6. Briefly spin the Detection Antibody vial (Item F) before use. Add 100 μl of 1x Assay Diluent into the vial to prepare a detection antibody concentrate. Pipette up and down to mix gently (the concentrate can be stored at 4°C for 5 days). The detection antibody concentrate should be diluted 100-fold with 1x Assay Diluent and used in step 4 of Part VI Assay Procedure.
7. Briefly spin the HRP-Streptavidin concentrate vial (Item G) and pipette up and down to mix gently before use. HRP-Streptavidin concentrate should be diluted 20,000-fold with 1x Assay Diluent. For example: Briefly spin the vial (Item G) and pipette up and down to mix gently . Add 2 μl of HRP-Streptavidin concentrate into a tube with 198.0 μl 1x Assay Diluent to prepare a 100-fold diluted HRP-Streptavidin solution (don’t store the diluted solution for next day use). Mix through and then pipette 70 μl of prepared 100-fold diluted solution into a tube with 14 ml 1x Assay Diluent to prepare a final 20,000 fold diluted HRP-Streptavidin solution.
Be sure to read ‘Preparation of Kit Reagents’ before carrying out the assay.
1. Bring all reagents and samples to room temperature (18 - 25°C) before use. It is recommended that all standards and samples be run at least in duplicate.
2. Add 100 μl of each standard (see Preparation of Kit Reagents: MMP9 Standard) and sample into appropriate wells. Cover and incubate for 2.5 hours at room temp. or overnight at 2-4°C with gentle shaking.
3. Discard the solution and wash 4 times with 1x Wash Solution. Wash by filling each well with Wash Buffer (300 μl) using a multi-channel pipette or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining wash buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
4. Add 100 μl of 1x prepared biotinylated antibody (see Preparation of Kit Reagents: Detection Antibody) to each well. Incubate for 1 hour at room temperature with gentle shaking.
5. Discard the solution and wash as in step 3 above.
6. Add 100 μl of prepared Streptavidin solution (see Preparation of Kit Reagents: Streptavidin-HRP Concentrate) to each well. Incubate for 45 minutes at room temperature with gentle shaking.
7. Discard the solution and wash as in step 3 above.
8. Add 100 μl of TMB One-Step Substrate Reagent (Item H) to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking.
9. Add 50 μl of Stop Solution (Item I) to each well. Read at 450 nm immediately.
Assay Procedure Summary
1. Prepare all reagents, samples and standards as instructed.
2. Add 100 μl standard or sample to each well. Incubate 2.5 hours at room temperature, or over night at 4°C.
3. Add 100 μl prepared Biotin antibody to each well. Incubate 1 hour at room temperature.
4. Add 100 μl prepared Streptavidin solution. Incubate 45 minutes at room temperature.
5. Add 100 μl TMB One-step Substrate Reagent to each well. Incubate 30 minutes at room temperature.
6. Add 50 μl Stop Solution to each well. Read at 450 nm immediately.
Calculation of Results
Calculate the mean absorbance for each set of duplicate standards, controls and samples, and subtract the average zero standard optical density. Plot the standard curve on log-log graph paper or using plot software, with standard concentration on the x-axis and absorbance on the y-axis. Draw the best-fit straight line through the standard points.
These standard curves are for demonstration only. A standard curve must be run with each assay.
Performances and Characteristics
The minimum detectable dose of MMP9 is typically less than 10 pg/ml.
Recovery was determined by spiking various levels of human MMP9 into human serum, plasma and cell culture media. Mean recoveries are as follows:
Cross Reactivity: This ELISA kit shows no cross-reactivity with any of the cytokines tested (e.g., human Angiogenin, BDNF, BLC, ENA-78, FGF4, IL1α, IL1β, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12 p70, IL12 p40, IL13, IL15, IL309, IP10, G-CSF, GM-CSF, IFN-γ, Leptin (OB), MCP1, MCP3, MDC, MIP1α, MIP1 β, MIP1δ, MMP1, -2, -3, -10, PARC, RANTES, SCF, TARC, TGF-β, TIMP1, TIMP2, TNF-α, TNF-β, TPO, VEGF).
Contact us about this product :
Our team will respond you as soon as possible !
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
email@example.com | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1004: Kit Receptor Signaling Pathway
WP1031: IL-3 Signaling Pathway
WP1060: Matrix Metalloproteinases
WP1065: Endochondral Ossification
WP1121: Kit Receptor Signaling Pathway
WP1150: IL-3 Signaling Pathway
WP1176: Matrix Metalloproteinases
WP1181: Endochondral Ossification
WP1270: Endochondral Ossification
WP129: Matrix Metalloproteinases
WP1308: Endochondral Ossification
WP1341: Kit Receptor Signaling Pathway
WP1359: IL-3 Signaling Pathway
WP1383: Endochondral Ossification
WP147: Kit Receptor Signaling Pathway
WP1993: angiogenesis overview
WP2107: pathways in human cancer
WP2256: Integrated Pancreatic Cancer Pathway
WP2377: Integrated Pancreatic Cancer Pathway
WP2411: Cancer prevention Q
WP2429: Cancer prevention Q
WP2431: Spinal Cord Injury
WP2432: Spinal Cord Injury
WP2433: Spinal Cord Injury
Related Genes :
[TP53 P53] Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)
[ELANE ELA2] Neutrophil elastase (EC 126.96.36.199) (Bone marrow serine protease) (Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN elastase)
[RACK1 GNB2L1 HLC7 PIG21] Receptor of activated protein C kinase 1 (Cell proliferation-inducing gene 21 protein) (Guanine nucleotide-binding protein subunit beta-2-like 1) (Guanine nucleotide-binding protein subunit beta-like protein 12.3) (Human lung cancer oncogene 7 protein) (HLC-7) (Receptor for activated C kinase) (Small ribosomal subunit protein RACK1) [Cleaved into: Receptor of activated protein C kinase 1, N-terminally processed (Guanine nucleotide-binding protein subunit beta-2-like 1, N-terminally processed)]
[AR DHTR NR3C4] Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptor subfamily 3 group C member 4)
[EGFR ERBB ERBB1 HER1] Epidermal growth factor receptor (EC 188.8.131.52) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
[SCN5A] Sodium channel protein type 5 subunit alpha (HH1) (Sodium channel protein cardiac muscle subunit alpha) (Sodium channel protein type V subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.5)
[FBN1 FBN] Fibrillin-1 [Cleaved into: Asprosin]
[CTNNB1 CTNNB OK/SW-cl.35 PRO2286] Catenin beta-1 (Beta-catenin)
[CCNDBP1 DIP1 GCIP HHM] Cyclin-D1-binding protein 1 (Grap2 and cyclin-D-interacting protein) (Human homolog of Maid)
[F8 F8C] Coagulation factor VIII (Antihemophilic factor) (AHF) (Procoagulant component) [Cleaved into: Factor VIIIa heavy chain, 200 kDa isoform; Factor VIIIa heavy chain, 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain]
[SIRT1 SIR2L1] NAD-dependent protein deacetylase sirtuin-1 (hSIRT1) (EC 3.5.1.-) (Regulatory protein SIR2 homolog 1) (SIR2-like protein 1) (hSIR2) [Cleaved into: SirtT1 75 kDa fragment (75SirT1)]
[BRCA1 RNF53] Breast cancer type 1 susceptibility protein (EC 184.108.40.206) (RING finger protein 53) (RING-type E3 ubiquitin transferase BRCA1)
[AKAP13 BRX HT31 LBC] A-kinase anchor protein 13 (AKAP-13) (AKAP-Lbc) (Breast cancer nuclear receptor-binding auxiliary protein) (Guanine nucleotide exchange factor Lbc) (Human thyroid-anchoring protein 31) (Lymphoid blast crisis oncogene) (LBC oncogene) (Non-oncogenic Rho GTPase-specific GTP exchange factor) (Protein kinase A-anchoring protein 13) (PRKA13) (p47)
[UBE3A E6AP EPVE6AP HPVE6A] Ubiquitin-protein ligase E3A (EC 220.127.116.11) (E6AP ubiquitin-protein ligase) (HECT-type ubiquitin transferase E3A) (Human papillomavirus E6-associated protein) (Oncogenic protein-associated protein E6-AP) (Renal carcinoma antigen NY-REN-54)
[HBB] Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin]
[APP A4 AD1] Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Amyloid precursor protein) (Beta-amyloid precursor protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); C80; Gamma-secretase C-terminal fragment 59 (Amyloid intracellular domain 59) (AICD-59) (AID(59)) (Gamma-CTF(59)); Gamma-secretase C-terminal fragment 57 (Amyloid intracellular domain 57) (AICD-57) (AID(57)) (Gamma-CTF(57)); Gamma-secretase C-terminal fragment 50 (Amyloid intracellular domain 50) (AICD-50) (AID(50)) (Gamma-CTF(50)); C31]
[gag-pol] Gag-Pol polyprotein (Pr160Gag-Pol) [Cleaved into: Matrix protein p17 (MA); Capsid protein p24 (CA); Spacer peptide 1 (SP1) (p2); Nucleocapsid protein p7 (NC); Transframe peptide (TF); p6-pol (p6*); Protease (EC 18.104.22.168) (PR) (Retropepsin); Reverse transcriptase/ribonuclease H (EC 22.214.171.124) (EC 126.96.36.199) (EC 188.8.131.52) (Exoribonuclease H) (EC 184.108.40.206) (p66 RT); p51 RT; p15; Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-)]
[ZAK MLTK HCCS4] Mitogen-activated protein kinase kinase kinase MLT (EC 220.127.116.11) (Human cervical cancer suppressor gene 4 protein) (HCCS-4) (Leucine zipper- and sterile alpha motif-containing kinase) (MLK-like mitogen-activated protein triple kinase) (Mixed lineage kinase-related kinase) (MLK-related kinase) (MRK) (Sterile alpha motif- and leucine zipper-containing kinase AZK)
[GOLGA2] Golgin subfamily A member 2 (130 kDa cis-Golgi matrix protein) (GM130) (GM130 autoantigen) (Golgin-95)
[LRRK2 PARK8] Leucine-rich repeat serine/threonine-protein kinase 2 (EC 18.104.22.168) (Dardarin)
[TGFB1 TGFB] Transforming growth factor beta-1 (TGF-beta-1) [Cleaved into: Latency-associated peptide (LAP)]
[AKT1 PKB RAC] RAC-alpha serine/threonine-protein kinase (EC 22.214.171.124) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)
[EPHA3 ETK ETK1 HEK TYRO4] Ephrin type-A receptor 3 (EC 126.96.36.199) (EPH-like kinase 4) (EK4) (hEK4) (HEK) (Human embryo kinase) (Tyrosine-protein kinase TYRO4) (Tyrosine-protein kinase receptor ETK1) (Eph-like tyrosine kinase 1)
[DNAJA1 DNAJ2 HDJ2 HSJ2 HSPF4] DnaJ homolog subfamily A member 1 (DnaJ protein homolog 2) (HSDJ) (Heat shock 40 kDa protein 4) (Heat shock protein J2) (HSJ-2) (Human DnaJ protein 2) (hDj-2)
[TRIP13 PCH2] Pachytene checkpoint protein 2 homolog (Human papillomavirus type 16 E1 protein-binding protein) (16E1-BP) (HPV16 E1 protein-binding protein) (Thyroid hormone receptor interactor 13) (Thyroid receptor-interacting protein 13) (TR-interacting protein 13) (TRIP-13)
[SRC SRC1] Proto-oncogene tyrosine-protein kinase Src (EC 188.8.131.52) (Proto-oncogene c-Src) (pp60c-src) (p60-Src)
[SCN1A NAC1 SCN1] Sodium channel protein type 1 subunit alpha (Sodium channel protein brain I subunit alpha) (Sodium channel protein type I subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.1)
[APOE] Apolipoprotein E (Apo-E)
[KCNQ1 KCNA8 KCNA9 KVLQT1] Potassium voltage-gated channel subfamily KQT member 1 (IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1) (KQT-like 1) (Voltage-gated potassium channel subunit Kv7.1)
[FGFR2 BEK KGFR KSAM] Fibroblast growth factor receptor 2 (FGFR-2) (EC 184.108.40.206) (K-sam) (KGFR) (Keratinocyte growth factor receptor) (CD antigen CD332)
 Piecemeal mechanism combining sprouting and intussusceptive angiogenesis in intravenous papillary formation induced by PGE2 and glycerol.
 Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.
 Activation Mechanisms of αVβ3 Integrin by Binding to Fibronectin: A Computational Study.
 Academic Difficulties in Children with Prenatal Alcohol Exposure: Presence, Profile, and Neural Correlates.
 P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
 MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2.
 MicroRNA-4739 regulates osteogenic and adipocytic differentiation of immortalized human bone marrow stromal cells via targeting LRP3.
 Metabolic profiling of tyrosine, tryptophan, and glutamate in human urine using gas chromatography-tandem mass spectrometry combined with single SPE cleanup.
 Using UHPLC Q-Trap/MS as a complementary technique to in-depth mine UPLC Q-TOF/MS data for identifying modified nucleosides in urine.
 Additive effects prevail: The response of biota to multiple stressors in an intensively monitored watershed.
Enter catalog number :